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Abstract 
Background 
Genetic variations in TGFB1 gene have been studied in relation to coronary heart disease 
(CHD) risk, but the results were inconsistent. 
Methods 
We performed a systematic review of published studies on the potential role of TGFB1 
genetic variation in CHD risk. Articles that reported the association of TGFB1 genetic 
variants with CHD as primary outcome were searched via Medline and HuGE Navigator 
through July 2011. The reference lists from included articles were also reviewed. 
Results 
Data were available from 4 studies involving 1777 cases and 7172 controls for rs1800468, 7 
studies involving 5935 cases and 10677 controls for rs1800469, 7 studies involving 6634 
cases and 9620 controls for rs1982073, 5 studies involving 5452 cases and 9999 controls for 
rs1800471, and 4 studies involving 5143 cases and 4229 controls for rs1800472. The pooled 
odds ratios (ORs) for CHD among minor T allele carriers of rs1800469, minor C allele 
carriers of rs1982073, and minor C allele carriers of rs1800471 versus homozygous major 
allele carriers was 1.14 (95 % confidence interval [CI]: 1.05-1.24), 1.18 (95 % CI: 1.04-1.35), 
and 1.16 (95 % CI: 1.02-1.32), respectively. No substantial heterogeneity for ORs was 
detected among the included Caucasian populations for all SNPs. However, for rs1800471, 
the statistical significance disappeared after adjusting for potential publication bias. No 
significant association was found between rs1800468 and rs1800472 variants and CHD risk. 
Conclusion 
Minor allele carriers of two genetic variants (rs1800469 and rs1982073) in TGFB1 have a 15 
% increased risk of CHD. 
Background 
Transforming growth factor-β1 (TGFβ1) is a ubiquitously expressed multifunctional cytokine 
that is involved in many physiological and pathological processes. TGFβ1 has been 
demonstrated to be of fundamental importance in the development, physiology and pathology 
of the vascular system. Research into the mechanisms of TGFβ1 signaling over the past two 
decades has led to the development of a well-accepted canonical signaling cascade involving 
heterotetrameric complexes of type I and type II serine/threonine-kinase transmembrane 
receptors together with Smad transcription factors that act as intracellular signaling effectors. 
However, the exact mechanisms by which TGFβ1 signaling exerts its effects within the 
vasculature are still incompletely understood [1-4]. According to the literature [2-7], TGFβ1 
can be secreted by several cell types, including peripheral blood mononuclear cells, 
macrophages, platelets, endothelial cells, vascular smooth muscle cells (VSMCs), 
myofibroblasts, and renal cells. Its regulatory function on the vessel wall is directed at 
endothelial cells, VSMC and extracellular matrix [1-3,5-8]. Although the role of TGFβ1 in 
the pathogenesis of atherosclerosis is being recognized, the association between plasma 
TGFβ1 levels and coronary heart disease (CHD) risk is still controversial [6,9-11]. There may 
be several explanations for the controversy: 1), TGFβ1 is a bimodal regulator of both 
endothelial cells and VSMC proliferation, depending on local TGFβ1 levels, cell density, 
and/or membrane TGFβ receptors [1,2,5,7,8,12]; 2), different pathophysiological stages of 
CHD may differentially affect the biological effects of TGFβ1 [1,3,10]; and 3), circulating 
TGFβ1 levels may not reflect the real vascular interstitial TGFβ1 levels that are directly 
involved in the pathogenesis of CHD [3-5,13]. Also, animal-model studies of CHD reported 
inconsistent findings on the role of TGFβ1 in CHD development. This might, however, be 
due to the dysregulated systemic immune function from different methods used, i.e. injecting 
TGFβ1 antibodies, infusing a soluble TGFβ receptor, or using transgenic or knockout mice 
[6,8]. 
Although the amino acid sequence of the active form of TGFβ1 is highly conserved across 
mammalian species [7,14,15], common TGFB1 genetic variations that could cause variable 
constitutive or induced expression of TGFB1 or protein structural changes and, as a result, 
changed TGFβ1 activity, have been identified. They include rs1800468 (−800 G/A) and 
rs1800469 (−509 C/T) in the promoter region, rs1982073 (868 T/C, Leu10Pro) and 
rs1800471 (913 G/C, Arg25Pro) in the signal peptide region, and rs1800472 (11929 C/T, 
Thr263Ile) in the region encoding the precursor part of the protein [4,15-19]. These genetic 
variants are generally in strong linkage disequilibrium (LD) with each other, and this DNA 
LD block covers the whole 5′ proximal region of the TGFB1 gene in Caucasian populations 
[4,14,16,17]. The minor alleles of these genetic variants or the haplotypes where the minor 
alleles are located, were associated with increased CHD risk in some [11,16,20], but not all 
studies [10,14,21,22], and even an opposite association has been observed [23]. This may 
partly be explained by a relatively small sample size, different CHD endpoints and/or 
different study populations in each of the published studies. Demonstrating an association 
may require a much larger number of subjects, which may be beyond the resource of one 
single study. Multiple replicated loci have recently been identified from genome-wide 
association (GWA) studies of CHD. However, they together explain only a small part of its 
heritability [24,25]. It has been suggested that the adopted highly stringent statistical criteria 
and/or the imperfect coverage of genetic variants by current GWA studies might prevent the 
discovery of potential loci associated with CHD risk [26]. No meta-analysis describing 
TGFB1 genetic variants in relation to CHD risk exists; therefore, we performed a meta-
analysis of published data that tested for TGFB1 genetic variants associated with CHD risk. 
Methods 
Selection criteria 
For inclusion, studies 1) had to be case–control or cohort in design, 2) examined the 
association between TGFB1 gene polymorphisms and primary outcomes of CHD, coronary 
artery disease or myocardial infarction (MI), 3) used validated coronary heart disease 
phenotypes (diagnostic criteria included angiographically confirmed; elevations of cardiac 
enzymes, changes of electrocardiographic and clinical symptoms according to the World 
Health Organizations criteria; a documented history of coronary artery bypass graft, 
percutaneous transluminal coronary angioplasty, or percutaneous coronary intervention), and 
4) involved unrelated participants. 
Search strategy 
All studies reporting on the association between TGFB1 gene polymorphism and CHD risk 
published before July 2011 were identified by comprehensive electronic searches of Medline 
and HuGENet. Terms used for the searches were “TGFB1,” “ischemic heart disease,” 
“coronary heart disease,” “coronary artery disease,” “acute coronary syndrome,” “myocardial 
infarction,” and “angina pectoris” combined with “gene,” “genetic,” “variant,” “mutation” or 
“polymorphism.” Hand searches for related articles among the reference lists of included 
articles were also performed. If essential information of a study was not presented in the 
publication, authors were contacted for details. The study was excluded if the information 
could not be obtained. In addition, the relevant data from the two latest large-scale meta-
analyses of CHD GWA studies (PROCARDIS [25] and CARDIoGRAM [24]) were also 
included for part of the analysis. 
Data extraction 
The first author, published year, country, study population, mean age of participants, gender 
distribution, study design, sample size, outcome, diagnostic criteria, genotyping method, 
characteristics of the controls, allele frequencies, and genotype distributions were extracted. 
In PROCARDIS [25] and CARDIoGRAM [24], the studied SNPs were not available in the 
genome-wide genotyping assay and had to be imputed. The SNPs imputed with high quality 
(MACH_R2 > 0.3) were included in the analyses. 
Statistical analysis 
Deviance from Hardy-Weinberg equilibrium (HWE) was assessed for the controls of each 
study using Fisher’s exact test. For an Iranian study [11], only data on rs1982073 was utilized 
in the meta-analysis because other SNPs deviated from HWE. Genotype distributions of 
controls for studies with case–control design or the entire group for studies with cohort 
design were used to estimate the frequency of the putative risk allele for each SNP using the 
inverse variance method (Additional file 1) [27]. Crude ORs with 95 % confidence intervals 
(CI) were used to evaluate the association between genetic polymorphisms and CHD risk. 
Pooled ORs were calculated for several genetic models, i.e. the co-dominant model, the 
dominant model, and the recessive model. Since the co-dominant model effects (or additive 
model effects) cannot be straightforward calculated from the extracted summary data from 
each study, we presented the effects of two groups of genotype comparison (Additional file 
1). Since the using of best-guess genotype from the genotype imputation process can lead to 
both false positives and loss of power [28], the allele effects from the PROCARDIS [25] and 
CARDIoGRAM [24] studies were only included in part of the co-dominant model analyses 
(Additional file 1). Statistical heterogeneity in the ORs across studies was assessed with the 
Q-test. If there was heterogeneity, ethnicity as source of heterogeneity was explored by 
pooling the data from Caucasian populations only. If there was no heterogeneity, the fixed-
effect model was used to evaluate the overall gene effect; otherwise, the random-effect model 
was used. Presence of publication bias was explored with Begg’s funnel plot and Egger’s 
regression test. If potential publication bias existed, the Duval and Tweedie nonparametric 
“trim and fill” method [29] was used to adjust for it. All reported p values were two-tailed, 
and statistical significance was defined at the α = 0.05 level. All analyses were performed 
with the R metafor package [30]. 
Results 
Study inclusion and characteristics 
Fifteen citations were identified through the original literature search; none were meta-
analyses [10,11,14,16,20-23,31-37]. After full review, two studies were excluded because 
they were conducted in patient cohorts with a composite end-point that included CHD 
[31,32]. Three studies (two European [10,33] and one Japanese [34]) were conducted without 
“proper” controls of no CHD history and were also excluded. One additional Chinese study 
met the inclusion criteria but was excluded due to unavailability of essential information even 
after contacting the authors [35]. The 9 remaining studies, together with PROCARDIS [25] 
and CARDIoGRAM [24] studies, were included in the meta-analysis (Table 1) [11,14,16,20-
23,36,37]. 
Table 1 Characteristics of studies included in the meta-analysisa 
Study Country Design Cases Controls Outcome 
Genotypes Genotypes p_HWE 
c
 
 
rs1800468 
(−800 G/A) 
  N GG AG AA N GG AG AA   
Crobu et al, 
2008 [22] 
Italy CC 201 175 25 1 201 168 31 2 0.65 MI 
Sie et al, 2006 
[21] 
Netherlands CO 358 288 66 4 6098 5071 984 43 0.58 MI 
Syrris et 
al,1998 [14] 
England CC 655 541 110 4 244 207 36 1 1 CAD 
Cambien et 
al,1996 [16] 
FR and NIE CC 563 472 88 3 629 534 89 6 0.28 MI 
rs1800469 
(−509 C/T) 
   CC CT TT  CC CT TT   
Sudomoina et 
al, 2010 [36] b 
Russia CC 264 77 150 37 212 90 103 19 0.22 MI 
Drenos et al, 
2009 [37] 
England CC 240 120 100 20 2143 1090 885 168 0.56 CAD 
Crobu et al, 
2008 [22] 
Italy CC 201 67 87 47 201 80 92 29 0.76 MI 
Koch et al, 
2006 [20] 
Germany CC 3657 1581 1659 417 1211 564 508 139 0.13 MI 
Sie et al, 2006 
[21] 
Netherlands CO 355 171 156 28 6037 3043 2441 553 0.05 MI 
Syrris et al, 
1998 [14] 
England CC 655 301 284 70 244 124 97 23 0.54 CAD 
Cambien et al, 
1996 [16] 
FR and NIE CC 563 240 257 66 629 263 297 69 0.29 MI 
rs1982073 
(868 T/C) 
   TT TC CC  TT TC CC   
Najar et al, 
2011 [11] 
Iran CC 900 301 424 175 900 395 403 102 1 MI 
Crobu et al, 
2008 [22] 
Italy CC 201 55 88 58 201 69 101 31 0.66 MI 
Koch et al, 
2006 [20] 
Germany CC 3657 1235 1802 620 1211 458 565 188 0.55 MI 
Sie et al, 2006 
[21] 
Netherlands CO 343 135 164 44 5844 2322 2698 824 0.37 MI 
Yokota et al, 
2000 [23] 
Japan CC 315 89 185 41 591 149 295 147 1 MI 
Syrris et al, 
1998 [14] 
England CC 655 242 306 107 244 102 109 33 0.68 CAD 
Cambien et al, 
1996 [16] 
FR and NIE CC 563 181 277 105 629 225 297 107 0.62 MI 
rs1800471 
(913 G/C) 
   GG GC CC  GG GC CC   
Drenos et al, 
2009 [37] 
England CC 234 187 45 2 2071 1723 331 17 0.78 CAD 
Koch et al, 
2006 [20] 
Germany CC 3657 3149 486 22 1211 1063 141 7 0.33 MI 
Sie et al, 2006 
[21] 
Netherlands CO 343 297 45 1 5844 4992 823 29 0.51 MI 
Syrris et al, 
1998 [14] 
England CC 655 558 95 2 244 214 30 0 0.61 CAD 
Cambien et al, 
1996 [16] 
FR and NIE CC 563 464 92 7 629 546 81 2 1 MI 
rs1800472 
(11929 C/T) 
   CC CT TT  CC CT TT   
Drenos et al, 
2009 [37] 
England CC 241 234 7 0 2145 2052 89 4 0.02 CAD 
Koch et al, 
2006 [20] 
Germany CC 3657 3421 231 5 1211 1138 72 1 1 MI 
Syrris et al, 
1998 [14] 
England CC 655 622 33 0 244 237 7 0 1 CAD 
Cambien et al, 
1996 [16] 
FR and NIE CC 590 563 27 0 629 585 42 2 0.20 MI 
FR and NIE, France and Northern Ireland; CC, case–control; CO, cohort; MI, myocardial 
infarction; CAD, coronary artery disease 
a, For rs1800468, rs1982073 and rs1800471, 10090 additional subjects were included for the 
co-dominant model analysis from the PROCARDIS study [25]; for rs1800469, additional 
10090 and 80016 subjects were included for the co-dominant model analysis, respectively 
from the PROCARDIS study [25] and the CARDIoGRAM study [24] (Additional file 1) 
b, Additional unpublished data have been included 
c, The p values for Hardy-Weinberg equilibrium were derived from Fisher’s exact test 
Quantitative synthesis 
None of the genetic variants were associated with CHD risk when applying a recessive model 
(data not shown). Rs1800468 and rs1800472 were not associated with CHD in either co-
dominant or dominant model (Additional file 1). 
For rs1800469, both the CT genotype in the co-dominant model and the presence of the 
minor T allele in the dominant model conferred a risk for CHD when compared to the 
common CC genotype (OR = 1.14, 95 % CI: 1.04-1.25; and OR = 1.14, 95 % CI: 1.05-1.24, 
respectively). The TT genotype conferred a non-significant risk of similar magnitude (Figure 
1). For rs1982073, the TC genotype conferred a risk for CHD in the co-dominant model 
(OR = 1.18, 95 % CI: 1.08-1.28), but the CC genotype did not when compared to the common 
TT genotype (Figure 2). Under a dominant model, the presence of the minor C allele was 
associated with a 1.18 times increased risk for CHD (Additional file 1). 
Figure 1 Meta-analysis for coronary heart disease risk depending on the rs1800469 
(−509 C/T) polymorphism in the TGFB1 gene. ORs and corresponding 95 % confidence 
intervals (CIs) are shown. Fixed effects were reported because no significant heterogeneity 
between studies was observed. A. Comparison of the homozygous TT genotype with the wild 
type CC genotype (p = 0.08); B. Comparison of the heterozygous CT genotype with the wild 
type CC genotype (p = 0.004); C. Comparison of the TT + CT genotype with the wild type CC 
genotype (p = 0.003) 
Figure 2 Meta-analysis for coronary heart disease risk depending on the rs1982073 (868 
T/C) polymorphism in the TGFB1 gene. ORs and corresponding 95 % confidence intervals 
(CIs) are shown. A. Comparison of the homozygous CC genotype with the wild type TT 
genotype (random-effect model, p = 0.26); B. Comparison of the heterozygous TC genotype 
with the wild type TT genotype (random-effect model, p = 0.0002); C. Comparison of the 
CC + TC genotype with the wild type TT genotype (random-effect model, p = 0.01) 
For rs1800471, both the GC genotype in the co-dominant model and the presence of the 
minor C allele in the dominant model conferred a risk for CHD when compared to the 
common GG genotype (OR = 1.15, 95 % CI: 1.01-1.31; and OR = 1.16, 95 % CI: 1.02-1.32, 
respectively). The CC genotype conferred a 1.25 times increased risk, but this was not 
statistically significant (Figure 3). 
Figure 3 Meta-analysis for coronary heart disease risk depending on the rs1800471 (913 
G/C) polymorphism in the TGFB1 gene. ORs and corresponding 95 % confidence intervals 
(CIs) are shown. Fixed effects were reported because no significant heterogeneity between 
studies was observed. A. Comparison of the homozygous CC genotype with the wild type 
GG genotype (p = 0.49); B. Comparison of the heterozygous GC genotype with the wild type 
GG genotype (p = 0.03); C. Comparison of the GC + CC genotype with the wild type GG 
genotype (p = 0.02) 
After adjusting for multiple testing using Bonferroni correction, all significant associations 
for rs1800469 and rs1982073 under the co-dominant and dominant models remained. 
However, for rs1800471, associations were no longer statistically significant (p > 0.017 in 
Additional file 1). When the relevant allele effects from the PROCARDIS [25] and 
CARDIoGRAM [24] studies were included in the co-dominant model analyses, the 
aforementioned associations attenuated; however, the association for rs1982073 persisted 
(Additional file 1). 
No substantial heterogeneity for the ORs was detected among the included Caucasian 
populations (Additional file 1). For rs1982073, however, some heterogeneity existed between 
Caucasian populations and non-Caucasian populations with regard to both CC and (CC + TC) 
vs. TT contrasts (Additional file 1). 
Sensitivity analysis and publication bias 
To evaluate the influence of the individual studies on the pooled ORs for rs1800469, 
rs1982073 and rs1800471, each time, a single study involved in the meta-analysis was 
deleted. The Rotterdam study [21] and the Japanese study [23] tended to attenuate the pooled 
ORs in the co-dominant model for rs1800469 and rs1982073, respectively (Additional file 2). 
No substantial alteration in the observed pooled ORs was observed for rs1800471 (Additional 
file 2). Begg’s funnel plot and Egger’s regression test were performed to assess potential 
publication bias for rs1800469, rs1982073 and rs1800471. Although the P values for Egger’s 
regression tests for all investigated models were > 0.05, Begg’s funnel plot still suggested a 
certain degree of publication bias, potentially from small studies with significant positive 
results (Additional file 3). After performing the “trim and fill method” to adjust for potential 
publication bias, the results for rs1800469 and rs1982073 did not change significantly (data 
not shown). However, for rs1800471, the statistical significance for both co-dominant and 
dominant models disappeared (P = 0.07). 
Discussion 
Several studies have been carried out to test the hypothesis that genetic polymorphisms in the 
TGFB1 gene including rs1800468, rs1800469, rs1982073, rs1800471 and rs1800472 might 
be associated with CHD risk, but data have yielded conflicting results. Possible concerns in 
genetic association studies are that a positive association might be spurious, while a negative 
result might be due to a small sample size. In this meta-analysis, we incorporated all eligible 
studies to date and provided some evidence that rs1800469 and rs1982073 in the TGFB1 
gene are associated with CHD risk in Caucasian populations. The inconsistency between the 
previously reported results for these SNPs might be due to the small sample sizes in most of 
the studies, especially in combination with a modest effect. 
Circulating TGFβ1 levels are predominantly under genetic control with a heritability of 0.54 
[17]. Both the CHD-associated minor risk alleles of rs1800469 and rs1982073 correlate with 
an increase in gene expression, TGFβ1 secretion, and plasma TGFβ1 levels 
[4,11,15,17,19,23]. These similar observations might be due to the strong LD between them 
[4,14,16,17]. Shah et al. [18] demonstrated exclusively in vivo and in vitro recruitment of 
transcription regulator AP1 to -509 C (the major non-risk allele of rs1800469) leading to 
transcriptional repression of the TGFB1 gene. However, the exact functional variant in this 
gene region merits further identification. In support of the aforementioned positive 
association between CHD risk alleles of TGFB1 and increased TGFβ1 production, increased 
TGFβ1 levels were observed in different stages of plaque development in some histological 
studies [7,38-40]. In addition, enhanced TGFβ1 signalling is established to cause 
cartilaginous metaplasia of vascular media and progressive intima-media thickening after 
vascular injuries [2-5,7,8,12]. Interestingly, an increased TGFβ1 regulated gene expression 
was observed in both atherosclerotic and restenotic lesions [41]. Recently, the TGFβ1 
signalling pathway is suggested to be involved in the genetic determining of CHD for the 
most replicated 9p21.3 locus [42-44]. A genetic variant in the SMAD3 gene that encodes one 
of the downstream activating transcriptional mediators (Smad3) of TGFβ1 signalling [1,2] 
was associated with CHD risk in a GWA study [44], which was recently replicated in a large-
scale meta-analysis of CHD studies [45]. 
It has previously been shown that abnormal enlargement of human coronary arteries (positive 
remodelling and aneurysmal coronary lesions) occurs in response to the development of 
intimal plaque [46-49], which is correlated with future acute coronary syndromes and cardiac 
events [50,51]. A strong heritable component (h2 = 0.52) of such abnormal enlargement of the 
coronary artery in the pathogenesis of coronary artery disease was observed, especially in the 
proximal coronary artery [52,53]. Interestingly, the 9p21.3 locus is also associated with 
increased risk of abdominal aortic aneurysm [54-56] and intracranial aneurysm [57,58]. 
Recently, high plasma TGFβ1 levels have been implicated in the manifestation of aortic root 
dilation in Marfan syndrome [6,13,59]. Furthermore, genetic variations along the TGFβ1 
signalling pathway are associated with coronary artery aneurysm formation and aortic root 
dilation in Kawasaki diseases [60], whereas mutations in genes of TGFβ1 signalling pathway 
(TGFBR1, TGFBR2 [61,62], and SMAD3 [63]) or TGFβ1 inhibitor genes [64] are implicated 
in familial or syndromic forms of thoracic aortic aneurysms and dissection. Taken together, 
this points at altered vascular remodelling from increased TGFβ1 signalling in the 
pathogenesis of CHD. However, given the fact that TGFβ1 is produced by multiple lineages 
of resident cells in vascular wall and atherosclerotic lesion and the fact that it acts in an 
autocrine, paracrine, and endocrine fashion [4], it has been very difficult to pinpoint the exact 
cellular sources of TGFβ1 that are relevant for the pathogenesis of CHD. More research on 
this topic is warranted. 
Some limitations of this meta-analysis should be acknowledged. First, a relatively small 
number of studies for each SNP was included, and therefore we cannot rule out heterogeneity 
completely in Caucasian populations although most of the P values for Q-tests were > 0.05. 
Second, the results in the co-dominant model for rs1800469 and rs1982073 were dominated 
by the Rotterdam [21] and the Japanese study [23] as shown by the sensitivity analysis. 
However, this did not affect our main conclusions. Third, the potential publication bias of 
relatively small sample-sized studies might have affected the results, as there might be 
eligible studies with negative results that were not published. In the context of these 
limitations, our current results should be interpreted with caution. 
Conclusion 
In conclusion, the present study demonstrates an association between rs1800469 and 
rs1982073 in the TGFB1 gene and CHD risk in Caucasian populations. Enhanced TGFβ1 
signalling may therefore be involved in the pathogenesis of CHD. 
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